Your genetic code is unique. Your cancer treatment should be too.
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer.
We are advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Meet some of the employees who make Kura such a great place to work.
Kura Oncology Announces Proof of Concept in AITL, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in PTCL.
Targeting an Undruggable Oncogene: Tipifarnib and HRAS Mutant Tumors
Kura Oncology, Inc. (Headquarters)
3033 Science Park Road, Suite 220
San Diego, CA 92121
Kura Oncology, Inc. (Clinical Development)
55 Cambridge Parkway, Suite 101
Cambridge, MA 02142
Disclaimer: The information you have requested is not provided by Kura Oncology but by a third party and is not intended to be relied on for investment purposes. Kura Oncology does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom